iShares Biotechnology ETF
646 hedge funds and large institutions have $5.66B invested in iShares Biotechnology ETF in 2019 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 182 increasing their positions, 247 reducing their positions, and 82 closing their positions.
3.71% more ownership
Funds ownership: 71.65% → 75.36% (+3.7%)
2% more capital invested
Capital invested by funds: $5.57B → $5.66B (+$89.3M)
4% less funds holding
Funds holding: 670 → 646 (-24)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
17% less first-time investments, than exits
New positions opened: 68 | Existing positions closed: 82
26% less repeat investments, than reductions
Existing positions increased: 182 | Existing positions reduced: 247
35% less call options, than puts
Call options by funds: $560M | Put options by funds: $859M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$305M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$179M |
| 3 |
JP Morgan Chase
New York
|
+$64.3M |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$57.4M |
| 5 |
N
Natixis
Paris,
France
|
+$53.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$120M |
| 2 |
DFO
Duquesne Family Office
New York
|
-$88.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$82.4M |
| 4 |
Morgan Stanley
New York
|
-$64.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$53.8M |
IBB Hedge Fund Activity: Q2 2019 in Review
646 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2019, worth a combined $5.66B — up 1.6% from $5.57B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of IBB and 68 opened new positions — a net loss of 14 holders — while 247 trimmed existing stakes and 182 added.
The largest buyer was Bank of America, adding an estimated $305M. The largest seller was Goldman Sachs, cutting an estimated $120M.
- 646 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2019, down from 670 in Q1 2019.
- Funds reported $5.66B of iShares Biotechnology ETF stock for Q2 2019, up 1.6% quarter-over-quarter.
- 68 funds opened new iShares Biotechnology ETF positions in Q2 2019 and 82 closed out, a net change of -14 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2019 was Bank of America, an estimated $305M added.
- The largest iShares Biotechnology ETF seller in Q2 2019 was Goldman Sachs, an estimated $120M sold.
Based on aggregated 13F filings for Q2 2019.